List of Excipients in Branded Drug DIPHENHYDRAMINE

Generic Drugs Containing DIPHENHYDRAMINE

Company	Ingredient	NDC	Excipient
Micro Labs Limited	diphenhydramine hydrochloride	42571-169	HYDROCHLORIC ACID
Micro Labs Limited	diphenhydramine hydrochloride	42571-169	SODIUM HYDROXIDE
Micro Labs Limited	diphenhydramine hydrochloride	42571-169	WATER
Fresenius Kabi USA LLC	diphenhydramine hydrochloride	63323-664	HYDROCHLORIC ACID
Fresenius Kabi USA LLC	diphenhydramine hydrochloride	63323-664	SODIUM HYDROXIDE
Fresenius Kabi USA LLC	diphenhydramine hydrochloride	63323-664	WATER
Fresenius Kabi USA LLC	diphenhydramine hydrochloride	65219-820	HYDROCHLORIC ACID

What are the Most Frequently-Used Excipients in DIPHENHYDRAMINE?

# Of NDCs	Excipient
5	HYDROCHLORIC ACID
5	SODIUM HYDROXIDE
3	WATER

# Diphenhydramine Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Diphenhydramine is a mature, low-cost first-generation antihistamine with extensive generic and OTC competition. Its active-ingredient patent exclusivity has expired, and commercial value has shifted from molecule protection to formulation differentiation, regulatory execution, manufacturing efficiency, and channel-specific products. The strongest opportunities are sugar-free pediatric liquids, alcohol-free and preservative-minimized formulations, unit-dose hospital products, abuse-resistant or dose-controlled delivery systems, and topical products with improved sensory performance.

What is the current FDA and commercial status of diphenhydramine?

Diphenhydramine is marketed primarily as diphenhydramine hydrochloride and diphenhydramine citrate. It is available in oral tablets, capsules, liquids, chewables, topical creams and gels, sprays, and injectable products.

Attribute	Diphenhydramine position
Active ingredient	Diphenhydramine hydrochloride or citrate
Drug class	First-generation H1 antihistamine
Main uses	Allergy, common-cold symptom relief, itching, nighttime sleep aid, motion-related nausea
Prescription status	Prescription products remain available, including injectable products
OTC status	Covered by FDA OTC monograph conditions for antihistamine, sleep-aid, and certain topical products
Biosimilar exposure	None; diphenhydramine is a chemically synthesized small molecule
Core patent position	Originator and API patents are expired or commercially irrelevant
Primary differentiation	Excipients, delivery format, dosing convenience, sensory properties, packaging, and channel positioning
Main commercial risk	Low switching costs and high generic substitution

FDA labeling recognizes diphenhydramine hydrochloride as an antihistamine and nighttime sleep-aid active ingredient within applicable OTC regulatory frameworks. Oral sleep-aid products typically contain 25 mg diphenhydramine hydrochloride or an equivalent amount of diphenhydramine citrate, subject to the applicable monograph conditions and labeling requirements (FDA, 2022a; FDA, 2022b).

Commercial products include Benadryl-branded allergy products, store-brand generics, hospital injectable products, and sleep-aid products such as ZzzQuil formulations. The market is fragmented across manufacturers and private-label suppliers. Brand equity exists, but the active ingredient itself has limited pricing power.

What patents protect diphenhydramine products?

No commercially meaningful basic-composition patent protects diphenhydramine as an active ingredient. The relevant patent estate is primarily historical, formulation-specific, or associated with branded combination products.

API and composition patents

Diphenhydramine was discovered and commercialized decades ago. Any original compound patent protection has expired. Generic manufacturers can therefore compete on the same active ingredient without licensing an originator patent.

The practical IP barriers are:

• formulation patents covering a specific dosage form or delivery system;
• process patents covering manufacturing or purification;
• device patents covering dosing or administration components;
• trademark rights for brand names;
• trade secrets covering flavor systems, coating processes, suspension stabilization, and scale-up methods.

These rights generally do not prevent ordinary immediate-release diphenhydramine tablets, capsules, standard oral solutions, or conventional topical creams.

Formulation and delivery patents

Potentially protectable features include:

• taste-masked particles or coated crystals;
• orally disintegrating tablets;
• buccal or sublingual delivery;
• controlled-release matrices;
• transdermal systems;
• metered topical sprays;
• prefilled injectable devices;
• unit-dose packages with integrated dosing controls;
• formulations that improve suspension stability or reduce sedimentation;
• preservative-free multidose systems;
• abuse-deterrent or tamper-evident delivery systems.

Patent strength depends on whether the product provides a measurable technical effect. A claim directed only to combining diphenhydramine with routine excipients is vulnerable to obviousness and lack of meaningful unexpected results. A stronger filing would connect a defined excipient system to quantified performance, such as improved dose uniformity after storage, reduced bitterness, faster disintegration, lower preservative burden, or better skin tolerability.

How should excipients be selected for diphenhydramine oral products?

Diphenhydramine hydrochloride is water-soluble, which supports immediate-release tablets, capsules, oral solutions, and suspensions. Its bitter taste, sedating pharmacology, pediatric dosing challenges, and frequent use in combination products drive most excipient decisions.

Immediate-release tablets and capsules

A conventional tablet can use:

• microcrystalline cellulose or lactose as diluent;
• croscarmellose sodium, sodium starch glycolate, or crospovidone as disintegrant;
• povidone or hydroxypropyl cellulose as binder;
• magnesium stearate or sodium stearyl fumarate as lubricant;
• colloidal silicon dioxide as glidant;
• film-coating polymers such as hypromellose.

For a low-dose tablet, content uniformity is important because the active load may be small relative to the tablet mass. Direct compression is commercially attractive, but the formulation must control segregation and lubricant sensitivity.

A differentiated tablet could use a low-weight, rapid-disintegration platform. This may support easier swallowing and improved patient acceptance, but patent value is limited unless the product demonstrates a defined disintegration, dissolution, stability, or sensory advantage.

Oral liquids and suspensions

Oral liquids create the largest excipient opportunity because diphenhydramine products are frequently used by children and older adults.

A commercial formulation should evaluate:

• purified water as vehicle;
• glycerin, sorbitol, or propylene glycol for mouthfeel and solubilization;
• sodium citrate and citric acid for pH control;
• sucralose, acesulfame potassium, or a sugar system for sweetness;
• fruit flavors selected to mask bitterness;
• xanthan gum, hypromellose, or microcrystalline cellulose-carboxymethylcellulose for suspension control;
• sodium benzoate or potassium sorbate where permitted and justified;
• chelating agents such as disodium edetate when compatible with the formulation;
• antifoam agents where filling and shaking behavior require them.

The principal development problem is taste masking. Diphenhydramine has a strong bitter taste that can remain detectable after sweetening. A flavor-only approach may require high sugar or polyol loading and can produce an undesirable aftertaste. More defensible strategies include ion-pairing, polymer coating, microencapsulation, or coated multiparticulates.

Pediatric products should prioritize:

• alcohol-free formulation;
• low or no sucrose;
• low viscosity that still supports dose uniformity;
• a calibrated oral syringe;
• clear dosing instructions;
• child-resistant packaging;
• acceptable microbial control without excessive preservative concentration.

Sugar-free products can target diabetic consumers, dental-health positioning, and adult nighttime use. Polyols may improve mouthfeel but can create gastrointestinal tolerance concerns at higher doses.

Chewable tablets and orally disintegrating products

Chewables can reduce swallowing difficulty but intensify taste-masking requirements. Suitable excipient systems may include mannitol, xylitol, compressible sugars, crospovidone, flavor oils, and polymer-coated drug particles.

Orally disintegrating tablets can support an adult convenience product, but they are unlikely to command a durable premium unless they solve a specific problem. A rapid-melt product can be differentiated through:

• low friability;
• minimal grittiness;
• low residual bitterness;
• rapid wetting;
• stable performance under humidity exposure;
• packaging that protects against moisture.

A blister-based presentation may be more appropriate than a bottle because many fast-dissolving systems are moisture-sensitive.

What excipient strategies apply to topical diphenhydramine?

Topical diphenhydramine products compete on skin feel, drying time, residue, spreadability, and irritation rather than systemic pharmacokinetics.

Potential dosage forms include creams, gels, lotions, sprays, and roll-ons.

Creams and lotions

Oil-in-water emulsions can use:

• carbomer or acrylate thickeners;
• glyceryl stearate and fatty alcohols as consistency agents;
• medium-chain triglycerides or light emollients;
• polysorbates or other emulsifiers;
• humectants such as glycerin;
• pH adjusters;
• preservatives compatible with the emulsion.

A low-residue cream with rapid rub-in may perform better in consumer testing than a conventional petrolatum-heavy base. The commercial target is a product for insect bites, minor irritation, and localized itching where consumers value immediate comfort and clean skin feel.

Gels and sprays

Hydroalcoholic gels can improve drying time and cooling sensation, but alcohol may irritate compromised skin and can create flammability and pediatric-use concerns. An alcohol-free gel using water, glycerin, carbomer, and a suitable neutralizer may offer broader use.

Metered sprays can improve contactless application and support outdoor, travel, and first-aid channels. The IP opportunity is stronger when the product combines a defined spray device with a formulation that delivers consistent dose per actuation.

Topical products must be evaluated for irritation, sensitization, microbial quality, preservative performance, and use on broken or inflamed skin. The product should not rely on a cosmetic-style sensory claim if the dosage form is regulated as a drug.

What manufacturing and excipient barriers affect commercial launch?

Diphenhydramine has a low-cost API supply base, so manufacturing barriers are usually operational rather than molecule-specific.

Oral manufacturing risks

Key risks include:

• powder segregation in low-dose tablets;
• sticking and picking during compression;
• lubricant overmixing and slow dissolution;
• sedimentation in suspensions;
• dose nonuniformity after storage;
• flavor loss;
• preservative failure;
• viscosity drift;
• extractables and leachables from plastic bottles;
• cap and syringe compatibility.

Suspensions require a controlled particle-size distribution and a reproducible redispersibility profile. A formulation that passes initial testing but forms a hard sediment during stability testing creates a material commercial risk.

Topical manufacturing risks

Topical products require control of:

• emulsion droplet size;
• viscosity;
• preservative distribution;
• filling accuracy;
• phase separation;
• spray-pattern uniformity;
• pump compatibility;
• microbial contamination.

A scalable product should be designed around common manufacturing equipment. Unusual excipients, specialty coated particles, or complex aseptic processes may increase cost beyond the achievable OTC price premium.

What is the Orange Book status of diphenhydramine?

The Orange Book is most relevant to approved prescription diphenhydramine products, including injectable products and other approved applications. OTC monograph products are not generally protected through the same Orange Book listing and Paragraph IV pathway used for approved prescription brand drugs.

The commercial implications are:

1. A conventional OTC monograph product does not normally require an ANDA against a listed reference drug.
2. An approved prescription product may have Orange Book-listed patents if applicable, but diphenhydramine’s basic active-ingredient protection is expired.
3. A novel prescription formulation may generate an NDA and potentially a new patent listing if the patent claims satisfy FDA listing rules.
4. OTC monograph reform under the CARES Act changed the administrative structure for nonprescription products, but it did not restore historical composition-patent exclusivity (FDA, 2022c).

The practical entry route depends on the final claims, dosage form, indication, labeling, and regulatory pathway. A standard oral OTC product can compete through monograph compliance. A novel delivery platform may require an NDA or another application-specific strategy.

When does diphenhydramine lose exclusivity?

Diphenhydramine’s core exclusivity has already expired. There is no conventional branded-product exclusivity timeline comparable to a recently approved small-molecule medicine.

Exclusivity category	Current position
Basic compound patent	Expired
Ordinary immediate-release formulation patents	Generally expired or commercially weak
New formulation patents	Possible, but product-specific
OTC monograph protection	Regulatory compliance, not market exclusivity
Orphan exclusivity	Not applicable to ordinary diphenhydramine products
Pediatric exclusivity	Not a current basis for broad market control
Biosimilar exclusivity	Not applicable
Trademark exclusivity	Available for brand identifiers, not the active ingredient

A new product may obtain patent protection around a delivery system or formulation, but that protection would be narrow. It would not block all generic diphenhydramine products.

Which commercial opportunities are most attractive?

The best opportunities are those where excipients solve a recognizable use problem and the product can be manufactured at OTC scale.

Opportunity	Excipient or design focus	Commercial rationale	IP potential
Sugar-free pediatric liquid	Polyol/sweetener system, flavor masking, oral syringe	Family and pediatric channels	Moderate if taste masking is technically defined
Alcohol-free topical gel	Carbomer or polymer gel, low-irritation system	Broader family use and improved tolerability	Moderate
Metered topical spray	Spray vehicle and dose-control device	Outdoor, travel, first-aid channels	Moderate to strong if device and formulation are integrated
Rapid-dissolve adult tablet	Mannitol, crospovidone, taste-masking coating	Convenience and swallowing support	Moderate
Preservative-minimized liquid	Packaging and antimicrobial control	Sensitive-skin and family positioning	Moderate
Hospital unit-dose injection	Prefilled syringe, low-sorption container, ready-to-use format	Reduces preparation steps and medication errors	Stronger device/process opportunity
Private-label platform	Common formulation base across strengths and brands	Contract manufacturing and retailer supply	Low molecule IP, high operational value
Combination cold product	Compatible excipient system for multiple actives	Shelf and channel expansion	Low to moderate, depending on formulation

Hospital products may offer better margins than commodity tablets, but they face higher quality, packaging, and supply-continuity expectations. Injectable diphenhydramine requires strict control of sterility, particulate matter, container closure, and extractables. A ready-to-administer presentation could create value without changing the active ingredient.

Which companies are challenging diphenhydramine products?

Competition is broad and fragmented. Major categories include:

• branded OTC suppliers;
• generic pharmaceutical manufacturers;
• private-label retailers;
• contract liquid and topical manufacturers;
• hospital injectable suppliers;
• specialty packaging and device companies.

Because the market is mature, commercial competition generally occurs through retailer contracts, pharmacy shelf placement, supply reliability, cost, and brand recognition. Publicly visible Paragraph IV litigation is not a central feature of the ordinary diphenhydramine market. Litigation risk is more likely to arise from branded combination products, trademarks, formulation claims, labeling, or manufacturing disputes than from the basic active ingredient.

What patent litigation and settlement risks exist?

A standard diphenhydramine tablet or liquid has limited patent-litigation exposure. The principal legal risks are:

• infringement claims involving a novel delivery system;
• patent disputes involving combination products;
• trade-secret claims concerning taste masking or manufacturing;
• trademark disputes involving brand names or packaging;
• ANDA litigation for an approved prescription formulation;
• product-liability claims associated with dosing errors or pediatric labeling.

Settlement agreements are not a material market-control mechanism for the ordinary active ingredient. A settlement could matter where a generic manufacturer challenges a specific branded formulation patent, but the outcome would normally affect only that formulation and not the broader diphenhydramine market.

How strong is the diphenhydramine patent estate?

The estate is weak for the active ingredient and potentially moderate for technically differentiated formulations.

IP asset	Strength assessment
Diphenhydramine compound claims	None of practical commercial value
Standard tablet formulation	Low
Standard oral solution	Low
Conventional cream or gel	Low
Taste-masked multiparticulates	Moderate
Metered topical delivery	Moderate
Prefilled injectable device	Moderate to strong
New controlled-release system	Moderate, subject to clinical and regulatory requirements
Manufacturing trade secrets	Potentially strong but difficult to enforce externally
Brand trademarks	Strong for brand identity, narrow against ingredient competition

Patent filings should focus on measurable technical parameters and multi-layer protection. A suitable portfolio could combine composition claims, particle or coating claims, manufacturing claims, device claims, and data-supported performance claims. The filing strategy should avoid broad claims that read directly on conventional excipient combinations.

What geographic coverage matters for diphenhydramine products?

The United States is a large and highly competitive OTC market, but the regulatory status of diphenhydramine differs by jurisdiction.

• In the United States, monograph compliance and FDA labeling govern many OTC products.
• In the European Union, diphenhydramine availability and indications vary by member state; sedating antihistamine use is subject to local regulatory treatment.
• In Canada, products are regulated under Health Canada’s nonprescription drug framework.
• In Australia and other markets, scheduling and permitted indications may restrict OTC positioning.
• In emerging markets, price and local manufacturing often outweigh formulation differentiation.

A global product should not assume that a U.S. OTC label, excipient system, or indication transfers directly to another jurisdiction. Colorants, preservatives, alcohol content, flavor systems, pediatric dosing, and claims may require country-specific changes.

What generic launch scenarios exist for new diphenhydramine products?

Commodity launch

A conventional tablet, capsule, liquid, or cream can launch quickly through an established OTC or generic pathway. The principal competitive advantages are cost, supply reliability, and retailer access. Margins are likely to be compressed.

Differentiated OTC launch

A sugar-free, alcohol-free, low-residue, fast-dissolving, or taste-masked product can support a premium if consumer testing confirms a clear preference. The product requires stronger packaging, stability, sensory, and regulatory documentation.

Prescription formulation launch

A novel controlled-release or device-enabled product may pursue an NDA. This path creates greater regulatory cost and could support a defensible patent estate, but clinical and safety requirements rise substantially.

Institutional launch

A ready-to-administer injectable, prefilled syringe, or unit-dose package can target hospitals and emergency departments. The value proposition is workflow efficiency and dose control, not a new pharmacological effect.

Key Takeaways

• Diphenhydramine’s basic composition and historical active-ingredient exclusivity are expired.
• The active ingredient has no biosimilar issue and limited Paragraph IV relevance in ordinary OTC products.
• Formulation, device, packaging, and manufacturing patents are the main remaining IP opportunities.
• Pediatric liquids offer the clearest excipient-led opportunity through taste masking, sugar reduction, alcohol removal, and dosing accuracy.
• Topical sprays and alcohol-free gels can differentiate through sensory performance and dose control.
• Prefilled injectable products may offer stronger institutional economics than commodity tablets.
• Ordinary excipient substitutions are unlikely to create durable patent protection without measurable technical results.
• The market is heavily exposed to generic competition, retailer pricing, and private-label substitution.
• Brand trademarks and channel access may be more commercially valuable than active-ingredient patents.
• Any premium product must demonstrate a concrete benefit in stability, tolerability, dosing accuracy, sensory quality, or workflow efficiency.

FAQs

Can diphenhydramine be protected with a new excipient combination?

Yes, but protection is more credible when the combination produces a documented technical effect, such as improved taste masking, dissolution, dose uniformity, stability, or skin tolerability.

Is diphenhydramine suitable for an orally disintegrating tablet?

Yes. Its low dose and immediate-release profile are compatible with an orally disintegrating platform, although bitterness and moisture sensitivity require careful formulation and packaging.

What is the best preservative strategy for diphenhydramine syrup?

The strategy depends on pH, packaging, microbial challenge-test results, and intended shelf life. A preservative system may use benzoate or sorbate chemistry, but preservative minimization through packaging and formulation control can support differentiation.

Can a diphenhydramine product qualify for 180-day generic exclusivity?

A conventional OTC monograph product generally does not follow the ANDA Paragraph IV framework that creates 180-day generic exclusivity. The answer may differ for an approved prescription product and its specific regulatory pathway.

Does diphenhydramine have biosimilar competition?

No. Diphenhydramine is a chemically synthesized small molecule, so competition comes from generic and branded-equivalent products rather than biosimilars.

References

1. U.S. Food and Drug Administration. (2022a). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-341

2. U.S. Food and Drug Administration. (2022b). 21 C.F.R. Part 338: External analgesic drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-338

3. U.S. Food and Drug Administration. (2022c). Over-the-counter monograph reform under the Coronavirus Aid, Relief, and Economic Security Act. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.